Drug Profile
1ST 201
Alternative Names: 1ST-201Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator 1St Biotherapeutics
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Dendritic cell modulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for research development in Cancer in South Korea (Parenteral)
- 23 Sep 2020 Early research in Cancer is ongoing in South Korea (1St Biotherapeutics pipeline, September 2020)
- 08 Nov 2017 Early research in Cancer in South Korea before November 2017 (1ST Bio Therapeutics pipeline, November 2017)